Newer antipsychotics and upcoming molecules for schizophrenia.

Article Details

Citation

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA

Newer antipsychotics and upcoming molecules for schizophrenia.

Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2.

PubMed ID
23545936 [ View in PubMed
]
Abstract

BACKGROUND: The management of schizophrenia has seen significant strides over the last few decades, due to the increasing availability of a number of antipsychotics. Yet, the diminished efficacy in relation to the negative and cognitive symptoms of schizophrenia, and the disturbing adverse reactions associated with the current antipsychotics, reflect the need for better molecules targeting unexplored pathways. PURPOSE: To review the salient features of the recently approved antipsychotics; namely, iloperidone, asenapine, lurasidone and blonanserin. METHODS: We discuss the advantages, limitations and place in modern pharmacotherapy of each of these drugs. In addition, we briefly highlight the new targets that are being explored. RESULTS: Promising strategies include modulation of the glutamatergic and GABAergic pathways, as well as cholinergic systems. CONCLUSIONS: Although regulatory bodies have approved only a handful of antipsychotics in recent years, the wide spectrum of targets that are being explored could eventually bring out antipsychotics with improved efficacy and acceptability, as well as the potential to revolutionize psychiatric practice.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
IloperidoneAlpha-1A adrenergic receptorProteinHumans
Unknown
Antagonist
Details
IloperidoneDopamine D3 receptorProteinHumans
Unknown
Antagonist
Details
Lurasidone5-hydroxytryptamine receptor 1AProteinHumans
Unknown
Antagonist
Details
Lurasidone5-hydroxytryptamine receptor 2AProteinHumans
Yes
Antagonist
Details
Lurasidone5-hydroxytryptamine receptor 7ProteinHumans
Unknown
Antagonist
Details
LurasidoneAlpha-2C adrenergic receptorProteinHumans
Unknown
Antagonist
Details
LurasidoneDopamine D2 receptorProteinHumans
Yes
Antagonist
Details
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
LurasidoneCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Details